Human DAF on pig cells protects against human and non-human primate sera cytotoxicity mediated by exogenous or endogenous complement, as determined by flow cytometry

Transplant Immunology

Volumn 16, Issue 2, 2006, Pages 125-130

  Díaz Román, Tomás M ^a   Mañez, Rafael ^a,b   López Pelaez, Eduardo ^a   Centeno, Alberto ^a   Moscoso, Isabel ^a   Pértegaz, Sonia ^a   Doménech, Nieves ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cytotoxicity; DAF; Xenoantibodies; Xenotransplantation

Indexed keywords

ANTIBODY; DECAY ACCELERATING FACTOR; GALACTOSE ANTIBODY; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BABOON; CELL PROTECTION; COMPLEMENT SYSTEM; CYTOTOXICITY; FLOW CYTOMETRY; GRAFT REJECTION; HYPERACUTE GRAFT REJECTION; IMMUNOFLUORESCENCE; LYSIS; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC ANIMAL; TRANSGENICS; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, HETEROPHILE; ANTIGENS, CD55; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISACCHARIDES; FLOW CYTOMETRY; GRAFT REJECTION; HUMANS; LYMPHOCYTES; MODELS, BIOLOGICAL; ORGAN TRANSPLANTATION; PAPIO; SERUM; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 33746190636     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2006.03.008     Document Type: Article

References (33)

1. Cooper D.K.C. Clinical xenotransplantation-how close are we?. Lancet 362 (2003) 557-559
2. Schuurman H.J., Cheng J., and Lam T. Pathology xenograft rejection: a commentary. Xenotransplantation 9 (2002) 1-7
3. Lambrigts D., Sachs D.H., and Cooper D.K.C. Discordant organ xenotransplantation in primates: world experience and current status. Transplantation 66 (1998) 547-561
4. Cozzi E., Bhatti F., Schmoeckel M., Chavez G., Smith K.G., Zaidi A., et al. Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts. Transplantation 70 (2000) 15-21
5. Byrne G.W., McCurry K.R., Martin M.J., McClellan S.M., Platt J.L., and Logan J.S. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 63 (1997) 149-155
6. Samstein B., and Platt J.L. Physiologic and immunologic hurdles to xenotransplantation. J Am Soc Nephrol 12 (2001) 182-193
7. Loss M., Vangerow B., Schimidtko J., Kunz R., Jalali A., Arends H., et al. Acute vascular rejection is associated with systemic complement activation in a pig-to-primate kidney xenograft model. Xenotransplantation 7 (2000) 186-196
8. Logan J.S. Prospects for xenotransplantation. Curr Opin Immunol 12 (2000) 563-568
9. Manez R., Lopez-Pelaez E., Centeno A., Herrera J.M., Juffe A., Doménech N., et al. Transgenic expression in pig hearts of both hDAF and hMCP does not provide any additional benefit to that of hDAF alone in pig-to-baboon xenotransplantation. Transplantation 78 (2004) 930-933
10. Platt J., DiSesa V., Gail D., and Massicot-Fisher J. Recommendations of the National Heart, Lung, and Blood Institute Heart and Lung Xenotransplantation Working Group. Circulation 106 (2002) 1043-1047
11. Zhang H.F., Yu J., Chen S., Morgan B.P., Abagyan R., and Tomlinson S. Identificaction of the individual residues that determine human CD59 species selective activity. J Biol Chem 274 (1999) 10969-10974
12. Shin M.L., Hansch G., Hu V.W., and Nicholson-Weller A. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol 136 (1986) 1777-1782
13. Quigg R.J., Nicholson-Weller A., Cybulsky A.V., Badalamenti J., and Salant D.J. Decay accelerating factor regulates complement activation on glomerular epithelial cells. J Immunol 142 (1989) 877-882
14. Yamamoto H., Blaas P., Nicholsson-Weller A., and Hansch G.M. Homologous species restriction of complement-mediated killing of nucleated cells. Immunology 70 (1990) 422-426
15. Zhong R.K., Kozii R., and Ball E.D. Homologous restriction of complement-mediated cell lysis can be markedly enhanced by blocking decay-accelerating factor. Br J Haematol 91 (1995) 269-274
16. Díaz T.M., Pertega S., Ortega D., López E., Centeno A., Manez R., et al. An Fda/Pi flow cytometry assay of complement-mediated cytotoxicity of antibodies generated during xenotransplantation. Cytometry 62A (2004) 54-60
17. Boyumn A. Separation of leukocytes from blood and marrow. Introduction. Scand J Clin Lab Invest Suppl 97 (1968) 7
18. Von Krogh M. Colloidal chemistry and immunology. J Infect Dis 19 (1916) 452
19. Leatherbarrow R.J. Grafit user's guide version 4,0 (1998), Erithacus Software Ltd, Staines, UK 185-194
20. Taylor C.J., Tang K.G., Smith S.I., White D.J., and Davies H.F. HLA-specific antibodies in highly sensitized patients can cause a positive crossmatch against pig lymphocytes. Transplantation 65 (1998) 1634-1641
21. Muir R. On the relationship between the complements and immune bodies of different animals. J Pathol Bacteriol 16 (1911) 523
22. Houle J.J., and Hoffmann E.M. Evidence for restriction of the ability of complement to lyse homologous erythrocytes. J Immunol 133 (1984) 1444-1452
23. Ish C., Ong G.L., Desai N., and Mattes M.J. The specificity of alternative complement pathway-mediated lysis of erythrocytes: a survey of complement and target cells from 25 species. Scand J Immunol 38 (1993) 113-122
24. Galili U., Rachmilewitz E.A., Peleg A., and Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 160 (1984) 1519-1531
25. Good A.H., Cooper D.K.C., Malcolm A.J., Ippolito R.M., Koren E., Neethling F.A., et al. Identification of carbohydrate structures that bind human anti-porcine antibodies: implications for discordant xenografting in humans. Transplant Proc 24 (1992) 559-562
26. Cooper D.K.C., Good A.H., Koren E., Oriol R., Malcolm A.J., Ippolito R.M., et al. Identification of alpha-galactosyl and other carbohydratye epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1 (1993) 198-205
27. Kujundzic M., Koren E., Neethling F.A., Milotic F., Koscec M., Kujundzic T., et al. Variability of anti-αGal antibodies in human serum and their relation to serum cytotoxicity against pig cells. Xenotransplantation 1 (1994) 58-65
28. Neethling F.A., and Cooper D.K.C. Serum cytotoxicity to pig cells and anti-αGal antibody level and specificity in human and baboons. Transplantation 67 (1999) 658-665
29. Richards A.C., Davies H.F., McLaughlin M.L., Copeman L.S., Holmes B.J., Dos Santos Cruz G., et al. Serum anti-pig antibodies as potential indicators of acute humoral xenograft rejection in pig-tocynomolgus monkey kidney transplantation. Transplantation 73 (2002) 881-889
30. Diaz T.M., Moscoso I., Centeno A., Lopez-Pelaez E., Ortega D., and Doménech N. Flow cytometry complement-mediated cytotoxicity assay detects baboon xenoantibodies directed to porcine epitopes undetected by hemolytic assay. Transpl Immunol 13 (2004) 313-317
31. Verbakel C.A., de Bruin R.W., Bonthuis F., Jonker M., Dekker S., Marquet R.L., et al. Contrast in the efficacy of hDAF mouse hearts between ex vivo perfusion and transplantation into primates. Xenotransplantation 8 (2001) 284-291
32. Carrington C.A., and dos Santos Cruz G. Effect of cell surface concentration of human DAF on transgenic pig aortic endothelial cells on the degree of protection afforded against human complement deposition. Xenotransplantation 8 (2001) 100-105
33. Harris C.L., Spiller O.B., and Morgan B.P. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology 100 (2000) 462-470